Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.
The popularity of GLP-1 weight-loss drugs has led to a surge in copycat medications as drug patents expire. Hims & Hers Health played a significant role in this trend by offering cheaper versions of these drugs, impacting the stocks of patent holders like Eli Lilly and Novo Nordisk.